



Formatted: Right

Clinical Policy: Moxetumomab ~~pasudotox~~ Pasudotox-tdfk (Lumoxiti)

Reference Number: LA.PHAR.398

Effective Date: 03.16.23

Last Review Date: ~~01.21.25~~ 05.21.24

Line of Business: Medicaid

[Revision Log](#)

Formatted Table

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

****Please note: This policy is for medical benefit****

Description

Moxetumomab pasudotox-tdfk (LumoxitiTM) is a CD22-directed cytotoxin.

FDA Approved Indication(s)

Lumoxiti is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).

Limitation(s) of use: Not recommended in patients with severe renal impairment ($\text{CrCl} \leq 29$ mL/min).

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Louisiana Healthcare Connections that Lumoxiti is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Hairy Cell Leukemia ~~(must meet all):~~

- ~~Authorization~~ Authorization is not permitted. Member may not initiate therapy with Lumoxiti. If member is currently using Lumoxiti, proceed to section II.A. Hairy Cell Leukemia for continued therapy (see Appendix ~~ED~~).

Approval duration: Not applicable

B. Other diagnoses/indications (must meet 1 or 2):

- ~~1.~~ If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
- If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53

Formatted

II. Continued Therapy

A. Hairy Cell Leukemia (must meet all):

CLINICAL POLICY

Moxetumomab ~~pasudotox~~ Pasudotox-tdfk



1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Lumoxiti for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. Member has not received ≥ 6 treatment cycles;
4. If request is for a dose increase, request meets one of the following (a or b):*
 - a. New dose does not exceed 0.04 mg/kg/dose (actual body weight) for three days of each 28-day cycle;
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*Prescribed regimen must be FDA-approved or recommended by NCCN.

Approval duration: 6 months (total of 6 cycles)

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – LA.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CLS: capillary leak syndrome

~~CR: complete response~~

FDA: Food and Drug Administration

HCL: hairy cell leukemia

HUS: hemolytic uremic syndrome

NCCN: National Comprehensive Cancer
Cancer

~~PNA: purine nucleoside analog~~

Formatted: Indent: Left: 0", First line: 0"

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name—	Dosing Regimen	Dose Limit/ Maximum Dose
cladribine (purine analog)	Adult dose: 0.09 mg/kg IV QD for 7 days (off label SC dosing has been evaluated.)	0.09 mg/kg/day
Nipent [®] (pentostatin) (purine analog)	Adult dose: 4 mg/m ² IV once every other week up to 6 months if failure to respond.	4 mg/m ² /dose once every other week

CLINICAL POLICY

Moxetumomab ~~pasudotox~~ Pasudotox-tdfk



Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Intron A [®] (interferon alfa-2b)	Adult dose: 2 million units/m ² IM or SC 3 times a week for up to 6 months if failure to respond.	2 million units/m ² /dose
Rituxan [®] (rituximab)	Off label adult dose: 375 mg/m ² IV weekly up to 10 weeks has been reported. (Micromedex)	Varies
Imbruvica [®] (ibrutinib)	Off label adult dose: 420 mg PO QD in 28-day cycles until unacceptable toxicity or progressive disease. (Jones 2016)	Varies
Zelboraf [®] (vemurafenib)	Off label adult dose: 960 mg PO BID for up to 24 weeks. (Clinical Pharmacology)	Varies

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Not applicable

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): none reported
- Boxed warning(s): capillary leak syndrome (CLS) and hemolytic uremic syndrome (HUS)

Appendix D: General Information

The National Comprehensive Cancer Network (NCCN) HCL treatment recommendations:

- ~~First line therapy: purine analogs (cladribine ± rituximab, Nipent[®] (pentostatin)).~~
- ~~Second line therapy for relapse/refractory or progressive disease:~~
 - ~~Disease relapse ≥ 2 years after achieving CR to initial therapy:~~
 - ~~Retreatment with the same purine analog ± rituximab~~
 - ~~An alternate purine analog ± rituximab~~
 - ~~Rituximab monotherapy if unable to receive a purine analog~~
 - ~~Disease relapse < 2 years or less than CR after initial therapy:~~
 - ~~An alternative purine analog ± rituximab~~
 - ~~Zelboraf[®] (vemurafenib) ± rituximab~~
 - ~~Peginterferon alfa 2a (may be substituted for other interferon preparations)~~
 - ~~Rituximab monotherapy if unable to receive purine analog~~
 - ~~Zelboraf (vemurafenib)~~
- ~~Third line therapy and beyond for progressive disease:~~
 - ~~Zelboraf (vemurafenib) ± rituximab~~
 - ~~Imbruvica[®] (ibrutinib)~~

Appendix E: Permanent Withdrawal of Lumoxiti from the US Market

- On November 18, 2022, AztraZeneca announced the decision to permanently discontinue Lumoxiti from the US market in July 2023. AztraZeneca advises distributors to stop all distribution in August 2023. Also starting in August 2023, AztraZeneca will request returns of Lumoxiti packs from distributors.

Formatted: Normal

CLINICAL POLICY

Moxetumomab ~~pasudotox~~ Pasudotox-tdfk



- The removal of Lumoxiti from the US market is not related to the safety or efficacy of the medicinal product. There has been very low clinical uptake of Lumoxiti since FDA approval, due to the availability of other treatment options and possibly due to the specialized complexity of administration, toxicity prophylaxis and safety monitoring needs for patients.
- Action required for prescribers: ~~physicians~~ Physicians should not initiate new treatment with Lumoxiti with immediate effect. Physicians who are currently treating patients with Lumoxiti will have adequate time to complete six cycles of treatment.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
HCL	0.04 mg/kg (actual body weight) IV on Days 1, 3, and 5 of each 28-day cycle. Continue treatment for maximum of 6 cycles, disease progression, or unacceptable toxicity.	0.04 mg/kg/dose (actual body weight) See <u>regimen</u>

VI. Product Availability

Single-dose vial: 1 mg

VII. References

- Lumoxiti Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; ~~November~~ February 2022. Available at: <https://www.lumoxiti.com/dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6510282-1a57-4614-9859-299a227a089c>. Accessed ~~June 30, 2023~~ July 17, 2024.
- ~~National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at neen.org. Accessed July 10, 2023.~~
- ~~National Comprehensive Cancer Network Guidelines. Hairy Cell Leukemia Version 1.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf. Accessed July 10, 2023.~~
- ~~4.2.~~ AstraZeneca. Important prescribing information update – permanent withdrawal of Lumoxiti from the US market. November 18, 2022. Available at: <https://www.lumoxiti.com/content/dam/open-digital/moxe-dtc/en/pdf/LUMOXITI-Prescribing-information.pdf-fda.gov/media/164425/download>. Accessed August 9, 2023 5, 2024.

Formatted: Font color: Auto

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPSC Codes	Description
J9313	Injection, moxetumomab pasudotox-tdfk, 0.01 mg

CLINICAL POLICY

Moxetumomab ~~pasudotox~~ Pasudotox-tdfk



Reviews, Revisions, and Approvals	Date	LDH Approval Date
Converted corporate to local policy	02.23	03.16.23
Updated criteria for other diagnoses/indications	06.25.23	10.05.23
Annual review: removed initial approval criteria for HCL due to manufacturer withdrawal, added Appendix E with details of market withdrawal; references reviewed and updated.	05.21.24	<u>08.20.24</u>
<u>Annual review: removed Appendix D and drugs listed in Appendix B as they are not relevant to current criteria; references reviewed and updated.</u>	<u>01.21.25</u>	

Formatted Table

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

CLINICAL POLICY

Moxetumomab ~~pasudotox~~ Pasudotox-tdfk



Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©202~~5~~⁴ Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.